Health Canada gives green light to new study investigating novel made-in-Canada drug candidate to prevent brain injury in hemodialysis patients

A groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate co-developed by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis.

Vasomune Therapeutics is an alumnus of our BDSP™ and CAAP® programs, and presented at the OBIO® Investment Summit.